SEARCH

SEARCH BY CITATION

References

  • 1
    DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190200.
    Direct Link:
  • 2
    Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003; 18: 10918.
  • 3
    Campos GM, Peters JH, DeMeester TR, Oberg S, Crookes PF, Mason RJ. The pattern of esophageal acid exposure in gastroesophageal reflux disease influences the severity of the disease. Arch Surg 1999; 134: 8827.
  • 4
    Baldi F, Ferrarini F, Longanesi A, Ragazzini M, Barbara L. Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci 1989; 34: 18903.
  • 5
    Ward BW, Wu WC, Richter JE, Lui KW, Castell DO. Ambulatory 24-h esophageal pH monitoring. Technology searching for a clinical application. J Clin Gastroenterol 1986; 8 (Suppl. 1): 5967.
  • 6
    Wiener GJ, Richter JE, Copper JB, Wu WC, Castell DO. The symptom index: a clinically important parameter of ambulatory 24-h esophageal pH monitoring. Am J Gastroenterol 1988; 83: 35861.
  • 7
    Singh S, Richter JE, Bradley LA, Haile JM. The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci 1993; 38: 14028.
  • 8
    Dekel R, Martinez-Hawthorne SD, Guillen RJ, Fass R. Evaluation of symptom index in identifying gastroesophageal reflux disease-related noncardiac chest pain. J Clin Gastroenterol 2004; 38: 249.
  • 9
    Breumelhof R, Smout AJ. The symptom sensitivity index: a valuable additional parameter in 24-h esophageal pH recording. Am J Gastroenterol 1991; 86: 1604.
  • 10
    Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ. The symptom-association probability: an improved method for symptom analysis of 24-h esophageal pH data. Gastroenterology 1994; 107: 17415.
  • 11
    Colas-Atger E, Bonaz B, Papillon E, et al. Relationship between acid reflux episodes and gastroesophageal reflux symptoms is very inconstant. Dig Dis Sci 2002; 47: 64551.
  • 12
    Taghavi SA, Ghasedi M, Saberi-Firoozi M, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005; 54: 106771.
  • 13
    Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120: 1599606.
  • 14
    Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100: 2839.
    Direct Link:
  • 15
    Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 2004; 99: 9916.
    Direct Link:
  • 16
    Katz PO. Lessons learned from intragastric pH monitoring. J Clin Gastroenterol 2001; 33: 10713.
  • 17
    Pleskow D, Rothstein R, Lo S, et al. Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. Gastrointest Endosc 2005; 61: 6439.
  • 18
    Eubanks TR, Omelanczuk P, Richards C, Pohl D, Pellegrini CA. Outcomes of laparoscopic antireflux procedures. Am J Surg 2000; 179: 3915.
  • 19
    Maqbool S, Bhat YM, Khandwala F, et al. Barrett's esophagus: How much acid suppression is enough? Predictors of response to high dose proton pump inhibitors. Am J Gastroenterol 2004; 99: S10.
  • 20
    Sharma P, Reker D, Weston A, et al. Normalization of intra-esophageal pH in patients with Barrett's esophagus (BE) on rabeprazole and relationship of pH to Barrett's length and hiatal hernia. Am J Gastroenterol 2002; 97: S37.
  • 21
    Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 98991.
  • 22
    Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 7116.
    Direct Link:
  • 23
    Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14: 597602.
  • 24
    Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 5967.
  • 25
    Tutuian R, Katz P, Castell D. A PPI is a PPI is a PPI: lessons learned from prolonged intragastric pH monitoring. Gastroenterology 2000; 118 (Suppl. 2, pt 1): A17. Abstract 332.
  • 26
    Miner Jr P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 261620.
    Direct Link:
  • 27
    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 150714.
  • 28
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 65665.
    Direct Link:
  • 29
    Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 57583.
    Direct Link:
  • 30
    Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002; 16: 44554.
  • 31
    Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000; 14: 70914.
  • 32
    Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 126772.
  • 33
    Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 123540.
  • 34
    Pehlivanov ND, Olyaee M, Sarosiek I, McCallum RW. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 2003; 18: 88390.
  • 35
    Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 152731.